regeneron glp-1 gip treatment muscle loss side effects From Fat Burn to Build: The Future of Obesity Medications beyond GLP- 1 Anti-obesity Medications and Muscle Loss

The main source of glucagon is the pancreatic -cell, while intestinal L-cells and neurons in the nucleus of the solitary tract are the principal producers of GLP-1

doi: 10.3390/cimb47020096 11 DingS.AlexanderE.LiangH.KulcharR

[DOI] [PMC free article] [PubMed] [Google Scholar] 952.Schwenk R.W., Baumeier C., Finan B., Kluth O., Brauer C., Joost H.G

The FDA has approved GLP-1 drugs for type 2 diabetes in all patients, while newer evidence supports their use in cardiovascular protection and prediabetes management

Its mode of action involves slowing down gastric emptying

A summary of all the CV events occurring during these trials are presented in Additional file 1: Table S1